Trial Title:
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients
NCT ID:
NCT05735834
Condition:
Splenic Marginal Zone Lymphoma
Conditions: Official terms:
Lymphoma
Lymphoma, B-Cell, Marginal Zone
Rituximab
Zanubrutinib
Study type:
Interventional
Study phase:
Phase 3
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Rituximab
Description:
Truxima concentrate for solution for infusion 500 mg/50 ml
Arm group label:
Arm A - Rituximab + Zanubrutinib
Arm group label:
Arm B - Rituximab
Other name:
Truxima
Intervention type:
Drug
Intervention name:
Zanubrutinib
Description:
Zanubrutinib 80 mg hard capsules
Arm group label:
Arm A - Rituximab + Zanubrutinib
Other name:
Brukinsa
Summary:
The goal of this clinical trial is to compare the efficacy and tolerability of the
combination of two medicinal products, rituximab, and zanubrutinib, compared to rituximab
monotherapy in patients with Splenic Marginal Zone Lymphoma (SMZL), previously untreated
and who need systemic treatment.
The main questions it aims to answer are:
- Is the combination rituximab and zanubrutinib a more effective therapy than
rituximab monotherapy?
- Is the combination therapy, rituximab and zanubrutinib, well tolerated?
Study participants will be put into one of the two treatment groups (rituximab and
zanubrutinib or rituximab alone) for a maximum of two years and will undergo regular
visits until three years from treatment start.
Detailed description:
Phase III, interventional, multicenter, open label, randomized study to evaluate whether
treatment with zanubrutinib in combination with rituximab will result in an improvement
in Progression Free Survival (PFS) compared to treatment with rituximab in patients with
previously untreated splenic marginal zone lymphoma (SMZL).
Approximately 120 subjects will be randomized in a 1:1 ratio to receive zanubrutinib and
rituximab (Treatment Arm A) or rituximab (Treatment Arm B). The study will include a
Screening Phase, a Treatment Phase, and a Follow-Up Phase.
Subjects with investigator-confirmed progressive disease (PD) according to the Lugano
2014 criteria or unacceptable toxicity, or investigator/subject decision must discontinue
study treatment.
Patients who complete the treatment and patients who will discontinue treatment for any
reason will enter the Follow-up Phase.
The Response Follow-up Phase will occur for subjects who complete the treatment or
discontinue for reasons other than disease progression and will include efficacy
assessments every 24 weeks until investigator-assessed disease progression.
Subjects with PD during the Response Follow-up Phase will continue to be followed in the
Survival Follow-up Phase.
An Independent Data Monitoring Committee (IDMC) will be responsible for independent
review of the interim safety analysis on the first 20 enrolled patients in the
experimental arm.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Ability to understand and willingness to sign a written informed consent in
accordance with ICH/GCP regulations before registration and prior to any
trial-specific procedures.
- Confirmed diagnosis of SMZL, including Matutes immunophenotype score <3, absence of
CD103 and CD25 expression by flow cytometry, absence of Cyclin D1, BCL6, and CD10
expression by immunohistochemistry, and absence of the MYD88 L265P mutation.
Patients with prominent splenomegaly and involvement of the splenic hilar and/or
extra hilar lymph nodes are eligible
- Previously untreated disease. Patients with prior hepatitis C virus (HCV) infection
who underwent HCV eradication and have persistent SMZL after 3 months
post-eradication can be included. Patients with previous splenectomy are excluded.
- Treatment needs according to the ESMO guideline criteria
- Measurable lesions
- Age ≥ 18 years.
- European Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- Absolute neutrophil count (ANC) ≥ 1.0 x 109/L, platelet count ≥ 50 x 109/L, Hb > 7.5
g/dl. Values below such thresholds are allowed if attributable to the underlying
lymphoma. Transfusions are allowed if clinically indicated during screening.
- Adequate hepatic and renal function and coagulation parameters
- Patient able and willing to swallow trial drugs as whole tablet/capsule
Exclusion Criteria:
- Previous splenectomy.
- Any systemic therapy for SMZL.
- Patients with central nervous system (CNS) involvement.
- Prior malignancy (other than the disease under study) within the past 2 years,
except for curatively treated basal or squamous skin cancer, superficial bladder
cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6
prostate cancer.
- Clinically significant cardiovascular disease
- History of cerebrovascular accident or intracranial hemorrhage within 6 months
before registration and known bleeding disorders (eg, von Willebrand's disease or
hemophilia).
- History of confirmed progressive multifocal leukoencephalopathy (PML).
- Concomitant diseases that require anticoagulant therapy with warfarin or
phenprocoumon or other vitamin K antagonists and patients treated with dual
anti-platelet therapy. Patients being treated with factor Xa inhibitors (eg,
rivaroxaban, apixaban, edoxaban), direct thrombin inhibitors (e. dabigatran) low
molecular weight heparin (LMWH), or single anti-platelet agents (eg. aspirin,
clopidogrel) can be included but must be properly informed about the potential risk
of bleeding.
- Malabsorption syndrome or other condition that precludes the enteral route of
administration.
- Any uncontrolled active systemic infection requiring intravenous antimicrobial
treatment.
- Known human immunodeficiency virus (HIV) infection.
- Active COronaVIrus Disease 19 (COVID-19) infection or non-compliance with the
prevailing hygiene measures regarding the COVID-19 pandemic.
- Active chronic hepatitis C or hepatitis B virus infection
- Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune.
thrombocytopenia) requiring steroid therapy with > 20 mg daily of prednisone dose or
equivalent.
- Known hypersensitivity to trial drugs or any component of the trial drugs.
- Concomitant treatment with strong CYP3A inducers or inhibitors
- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that in the opinion of the investigator may increase the risk associated
with trial participation or investigational product administration or may interfere
with the interpretation of trial results and/or would make the patient inappropriate
for enrolment into this trial.
- Pregnancy or breastfeeding.
- Concurrent participation in another therapeutic clinical trial.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Medical University of Vienna
Address:
City:
Vienna
Country:
Austria
Status:
Recruiting
Contact:
Last name:
Markus Raderer, MD
Email:
markus.raderer@meduniwien.ac.at
Investigator:
Last name:
Markus Raderer, MD
Email:
Principal Investigator
Facility:
Name:
Aarhus University Hospital
Address:
City:
Aarhus
Country:
Denmark
Status:
Not yet recruiting
Contact:
Last name:
Ida Sillesen, MD
Email:
idasille@rm.dk
Investigator:
Last name:
Ida Sillesen, MD
Email:
Principal Investigator
Facility:
Name:
Aarhus University Hospital
Address:
City:
Aarhus
Country:
Denmark
Status:
Not yet recruiting
Contact:
Last name:
Ida Blok Sillesen, MD
Email:
idasille@rm.dk
Investigator:
Last name:
Ida Blok Sillesen, MD
Email:
Principal Investigator
Facility:
Name:
Institut Bergonié
Address:
City:
Bordeaux
Zip:
33076
Country:
France
Status:
Recruiting
Contact:
Last name:
Fontanet Bijou, MD
Email:
f.bijou@bordeaux.unicancer.fr
Investigator:
Last name:
Fontanet Bijou, MD
Email:
Principal Investigator
Facility:
Name:
CHU de Grenoble
Address:
City:
Grenoble
Zip:
38043
Country:
France
Status:
Recruiting
Contact:
Last name:
Sylvain Carras, MD
Email:
scarras@chu-grenoble.fr
Investigator:
Last name:
Sylvain Carras, MD
Email:
Principal Investigator
Facility:
Name:
Hôpital Saint Louis
Address:
City:
Paris
Zip:
75475
Country:
France
Status:
Recruiting
Contact:
Last name:
Catherine Thieblemont, MD
Email:
catherine.thieblemont@aphp.fr
Investigator:
Last name:
Catherine Thieblemont, MD
Email:
Principal Investigator
Facility:
Name:
Hôpital Lyon-Sud
Address:
City:
Pierre-Bénite
Zip:
69495
Country:
France
Status:
Recruiting
Contact:
Last name:
Pierre Sesques, MD
Email:
pierre.sesques@chu-lyon.fr
Investigator:
Last name:
Pierre Sesques, MD
Email:
Principal Investigator
Facility:
Name:
CHRU Nancy Brabois
Address:
City:
Vandœuvre-lès-Nancy
Zip:
54511
Country:
France
Status:
Recruiting
Contact:
Last name:
Pierre Feugier, MD
Email:
p.feugier@chru-nancy.fr
Investigator:
Last name:
Pierre Feugier, MD
Email:
Principal Investigator
Facility:
Name:
IRCCS Istituto Tumori Giovanni Paolo II
Address:
City:
Bari
Zip:
70124
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Carla Minoia, MD
Email:
carlaminoia@libero.it
Investigator:
Last name:
Carla Minoia, MD
Email:
Principal Investigator
Facility:
Name:
IRCCS AOU di Bologna
Address:
City:
Bologna
Zip:
40138
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Pier Luigi Zinzani, MD
Email:
pierluigi.zinzani@unibo.it
Investigator:
Last name:
Pier Luigi Zinzani, MD
Email:
Principal Investigator
Facility:
Name:
ASST Spedali Civili di Brescia
Address:
City:
Brescia
Zip:
25123
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Antonella Anastasia, MD
Email:
antonella.anastasia@asst-spedalicivili.it
Investigator:
Last name:
Antonella Anastasia, MD
Email:
Principal Investigator
Facility:
Name:
A.O.U. Policlinico G. Rodolico-S. Marco
Address:
City:
Catania
Zip:
95123
Country:
Italy
Status:
Not yet recruiting
Contact:
Last name:
Annalisa Chiarenza, MD
Email:
annalisa.chiarenza@gmail.com
Investigator:
Last name:
Annalisa Chiarenza, MD
Email:
Principal Investigator
Facility:
Name:
IRCCS IRST Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Address:
City:
Meldola
Zip:
47014
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Pietro Rossi, MD
Email:
pietro.rossi@irst.emr.it
Investigator:
Last name:
Pietro Rossi, MD
Email:
Principal Investigator
Facility:
Name:
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Address:
City:
Milan
Zip:
20122
Country:
Italy
Status:
Not yet recruiting
Contact:
Last name:
Alessandro Noto, MD
Email:
alessandro.noto@policlinico.mi.it
Investigator:
Last name:
Alessandro Noto, MD
Email:
Principal Investigator
Facility:
Name:
IRCCS Ospedale San Raffaele
Address:
City:
Milan
Zip:
20132
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Lydia Scarfò, MD
Email:
scarfo.lydia@hsr.it
Investigator:
Last name:
Lydia Scarfò, MD
Email:
Principal Investigator
Facility:
Name:
ASST Grande Ospedale Metropolitano Niguarda
Address:
City:
Milan
Zip:
20162
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Anna Maria Frustaci, MD
Email:
Annamaria.frustaci@ospedaleniguarda.it
Investigator:
Last name:
Anna Maria Frustaci, MD
Email:
Principal Investigator
Facility:
Name:
Azienda Ospedaliero Universitaria Maggiore della Carità
Address:
City:
Novara
Zip:
28100
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Gloria Margiotta Casaluci, MD
Email:
gloria.margiotta@med.uniupo.it
Investigator:
Last name:
Gloria Margiotta Casaluci, MD
Email:
Principal Investigator
Facility:
Name:
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
Address:
City:
Palermo
Zip:
90146
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Caterina Patti, MD
Email:
k.patti@villasofia.it
Investigator:
Last name:
Caterina Patti, MD
Email:
Principal Investigator
Facility:
Name:
IRCCS Policlinico San Matteo
Address:
City:
Pavia
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Luca Arcaini, MD
Email:
arcaini@unipv.it
Investigator:
Last name:
Luca Arcaini, MD
Email:
Principal Investigator
Facility:
Name:
Ospedale Santa Maria delle Croci
Address:
City:
Ravenna
Zip:
48121
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Monica Tani, MD
Email:
monica.tani@auslromagna.it
Investigator:
Last name:
Monica Tani, MD
Email:
Principal Investigator
Facility:
Name:
USL-IRCCS of Reggio Emilia, Arcispedale Santa Maria Nuova
Address:
City:
Reggio Emilia
Zip:
42123
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Stefano Luminari, MD
Email:
stefano.luminari@ausl.re.it
Investigator:
Last name:
Stefano Luminari, MD
Email:
Principal Investigator
Facility:
Name:
Policlinico Tor Vergata
Address:
City:
Rom
Zip:
00133
Country:
Italy
Status:
Not yet recruiting
Contact:
Last name:
Massimiliano Postorino, MD
Email:
massimiliano.postorino@ptvonline.it
Investigator:
Last name:
Massimiliano Postorino, MD
Email:
Principal Investigator
Facility:
Name:
Policlinico Santa Maria alle Scotte
Address:
City:
Siena
Zip:
53100
Country:
Italy
Status:
Not yet recruiting
Contact:
Last name:
Emanuele Cencini, MD
Email:
emanuele.cencini@ao-siena.toscana.it
Investigator:
Last name:
Emanuele Cencini, MD
Email:
Principal Investigator
Facility:
Name:
Ospedale di Circolo e Fondazione Macchi - ASST dei Sette Laghi
Address:
City:
Varese
Zip:
21100
Country:
Italy
Status:
Not yet recruiting
Contact:
Last name:
Marco Brociner, MD
Email:
marco.brociner@asst-settelaghi.it
Investigator:
Last name:
Marco Brociner, MD
Email:
Principal Investigator
Facility:
Name:
Oslo University Hospital
Address:
City:
Oslo
Country:
Norway
Status:
Not yet recruiting
Contact:
Last name:
Bjørn Østenstad, MD
Email:
UXBJOS@ous-hf.no
Investigator:
Last name:
Bjørn Østenstad
Email:
Principal Investigator
Facility:
Name:
Hospedal Clinic de Barcelona
Address:
City:
Barcelona
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Laura Magnano mayer, MD
Email:
LCMAGNAN@clinic.cat
Investigator:
Last name:
Laura Magnano Mayer, MD
Email:
Principal Investigator
Facility:
Name:
Hospital del Mar
Address:
City:
Barcelona
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Sergio Pinzón, MD
Email:
sfpinzonmarino@psmar.cat
Investigator:
Last name:
Sergio Pinzón, MD
Email:
Principal Investigator
Facility:
Name:
Istitut Català d'Oncologia, Hospital Duran i Reynals
Address:
City:
Barcelona
Country:
Spain
Status:
Not yet recruiting
Contact:
Last name:
Eva Domingo, MD
Email:
edomingo@iconcologia.net
Investigator:
Last name:
Eva Domingo, MD
Email:
Principal Investigator
Facility:
Name:
Hospital Universitario Cruces
Address:
City:
Bilbao
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Xabier Martin Martitegui, MD
Email:
xabier.martinmartitegui@osakidetza.eus
Investigator:
Last name:
Xabier Martin Martitegui, MD
Email:
Principal Investigator
Facility:
Name:
Hospital Virgen Arrixaca
Address:
City:
El Palmar
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Antonio Salar
Email:
asalar@psmar.cat
Investigator:
Last name:
Antonio Salar
Email:
Principal Investigator
Facility:
Name:
Hospital 12 De Octubre
Address:
City:
Madrid
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Ana Jimenez Ubieto, MD
Email:
anitiju@hotmail.com
Investigator:
Last name:
Ana Jimenez Ubieto, MD
Email:
Principal Investigator
Facility:
Name:
Hospital Gregorio Marañón
Address:
City:
Madrid
Country:
Spain
Status:
Not yet recruiting
Contact:
Last name:
Marian Bastos, MD
Email:
marianabeatriz.bastos@salud.madrid.org
Investigator:
Last name:
Marian Bastos, MD
Email:
Principal Investigator
Facility:
Name:
Hospital Ramon y Cajal
Address:
City:
Madrid
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Javier Lopez, MD
Email:
jljimenez@salud.madrid.org
Investigator:
Last name:
Javier Lopez, MD
Email:
Principal Investigator
Facility:
Name:
Clinica Universidad de Navarra
Address:
City:
Pamplona
Country:
Spain
Status:
Not yet recruiting
Contact:
Last name:
Carlos Grande Garcia, MD
Email:
cgrandeg@unav.es
Investigator:
Last name:
Carlos Grande Garcia, MD
Email:
Principal Investigator
Facility:
Name:
Hospital De Salamanca
Address:
City:
Salamanca
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Norma Guiterrez, MD
Email:
normagu@usal.es
Investigator:
Last name:
Norma Guiterez, MD
Email:
Principal Investigator
Facility:
Name:
Hospital De Donostia
Address:
City:
San Sebastián
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Izaskun Zeberio, MD
Email:
IZASKUN.ZEBERIOETXETXIPIA@osakidetza.eus
Investigator:
Last name:
Izaskun Zeberio, MD
Email:
Principal Investigator
Facility:
Name:
Hospital Clinico De Valencia
Address:
City:
Valencia
Country:
Spain
Status:
Not yet recruiting
Contact:
Last name:
Alfonso Ortiz
Email:
alfon_7_10@hotmail.com
Investigator:
Last name:
Alfonso Ortez, MD
Email:
Principal Investigator
Facility:
Name:
Hospital Universitario Miguel Servet
Address:
City:
Zaragoza
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Araceli Rubio Martinez, MD
Email:
arubiom@salud.aragon.es
Investigator:
Last name:
Araceli Rubio Martinez, MD
Email:
Principal Investigator
Facility:
Name:
Karolinska University Hospital
Address:
City:
Stockholm
Country:
Sweden
Status:
Not yet recruiting
Contact:
Last name:
Bjørn Wahlin, MD
Email:
bjorn.wahlin@gmail.com
Investigator:
Last name:
Bjørn Wahlin, MD
Email:
Principal Investigator
Facility:
Name:
Oncology Institute of Southern Switzerland
Address:
City:
Bellinzona
Zip:
6500
Country:
Switzerland
Status:
Recruiting
Contact:
Last name:
Maria Cristina Pirosa, MD
Email:
maria.pirosa@eoc.ch
Investigator:
Last name:
Maria Cristina Pirosa, MD
Email:
Principal Investigator
Facility:
Name:
INSELSPITAL, Bern University Hospital
Address:
City:
Bern
Zip:
3010
Country:
Switzerland
Status:
Recruiting
Contact:
Last name:
Martin Andres, MD
Email:
Martin.Andres@insel.ch
Investigator:
Last name:
Martin Andres, MD
Email:
Principal Investigator
Facility:
Name:
Birmingham Hearthland Hospital
Address:
City:
Birmingham
Zip:
B95 SS
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
Swathy Srinath, MD
Email:
swathy.srinath2@uhb.nhs.uk
Investigator:
Last name:
Swathy Srinat, MD
Email:
Principal Investigator
Facility:
Name:
University Hospitals Dorset
Address:
City:
Bournemouth
Zip:
BH7 7DW
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
Renata Walewska, MD
Email:
Renata.Walewska@uhd.nhs.uk
Investigator:
Last name:
Renata Walewska, MD
Email:
Principal Investigator
Facility:
Name:
University Hospital of Wales
Address:
City:
Cardiff
Zip:
CF14 4XW
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
Simona Gatto, MD
Email:
Simona.Gatto@wales.nhs.uk
Investigator:
Last name:
Simona Gatto, MD
Email:
Principal Investigator
Facility:
Name:
Hospital Beatson West of Scotland Cancer Centre
Address:
City:
Glasgow
Zip:
G12 0YN
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Pam McKay, MD
Email:
Pam.McKay@ggc.scot.nhs.uk
Investigator:
Last name:
Pam McKay, MD
Email:
Principal Investigator
Facility:
Name:
Leicester Royal Infirmary
Address:
City:
Leicester
Zip:
LE1 5WW
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
Constantine-George Balotis, MD
Email:
Constantine.G.Balotis@uhl-tr.nhs.uk
Investigator:
Last name:
Constantine-George Balotis, MD
Email:
Principal Investigator
Facility:
Name:
Clatterbridge Cancer Centre
Address:
City:
Liverpool
Zip:
L7 8YA
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
Andrew Pettit, MD
Email:
arp@liverpool.ac.uk
Investigator:
Last name:
Andrew Pettit, MD
Email:
Principal Investigator
Facility:
Name:
University College London Hospitals
Address:
City:
London
Zip:
NW1 2PG
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
Satyen Gohil, MD
Email:
satyen.gohil@nhs.net
Investigator:
Last name:
Satyen Gohil, MD
Email:
Principal Investigator
Facility:
Name:
Guy's Hospital - Guy's and St. Thomas' NHS Foundation Trust
Address:
City:
London
Zip:
SE1 9RT
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
Suzanne Arulogun, MD
Email:
Suzanne.Arulogun@gstt.nhs.uk
Investigator:
Last name:
Suzanne Arulogun, MD
Email:
Principal Investigator
Facility:
Name:
The Christie
Address:
City:
Manchester
Zip:
M20 4BX
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Kim Linton
Email:
Kim.M.Linton@manchester.ac.uk
Investigator:
Last name:
Kim Linton, MD
Email:
Principal Investigator
Facility:
Name:
Churchill Hospital
Address:
City:
Oxford
Zip:
OX3 7LE
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
Xu Danmei, MD
Email:
danmei.xu@nhs.net
Investigator:
Last name:
Xu Danmei, MD
Email:
Principal Investigator
Facility:
Name:
Derriford Hospital
Address:
City:
Plymouth
Zip:
PL6 8DH
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
David Lewis, MD
Email:
david.lewis17@nhs.net
Investigator:
Last name:
David Lewis, MD
Email:
Principal Investigator
Facility:
Name:
University Hospitals Southampton
Address:
City:
Southampton
Zip:
SO16 6YD
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
Andrew Davies, MD
Email:
a.davies@soton.ac.uk
Investigator:
Last name:
Andrew Davies, MD
Email:
Principal Investigator
Facility:
Name:
The Royal Marsden NHS Foundation Trust
Address:
City:
Sutton
Zip:
SM2 5PT
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
Sunil Iyengar, MD
Email:
Sunil.iyengar@rmh.nhs.uk
Investigator:
Last name:
Sunil Iyengar, MD
Email:
Principal Investigator
Facility:
Name:
South Warwickshire University NHS Foundation Trust
Address:
City:
Warwick
Zip:
CV34 5BW
Country:
United Kingdom
Status:
Not yet recruiting
Contact:
Last name:
Anton Borg, MD
Email:
Anton.Borg@swft.nhs.uk
Investigator:
Last name:
Anton Borg, MD
Email:
Principal Investigator
Start date:
May 21, 2024
Completion date:
May 2029
Lead sponsor:
Agency:
International Extranodal Lymphoma Study Group (IELSG)
Agency class:
Other
Source:
International Extranodal Lymphoma Study Group (IELSG)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05735834
